• Corpus ID: 30038982

High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma.

@article{Jamali2000HighPL,
  title={High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma.},
  author={Fatemeh Jamali and Saeed Sattari},
  journal={Journal of pharmacy \& pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques},
  year={2000},
  volume={3 3},
  pages={
          312-7
        }
}
  • F. Jamali, S. Sattari
  • Published 1 September 2000
  • Chemistry
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
Rofecoxib is a relatively new non-steroidal anti-inflammatory drug with high selectivity in cyclooxygenase 2 inhibitory activity. There is only one assay reported for determination of the drug in biological samples. The assay requires a post-column UV reactor for photocyclization before detection with fluorescence detector. In addition, the internal standard (IS) used in the assay in not commercially available. We developed a new assay for determination of rofecoxib. Rat blank plasma (200… 

Figures and Tables from this paper

Simultaneous determination of rofecoxib and celecoxib in human plasma by high-performance liquid chromatography.
TLDR
The validation data show that the assay is sensitive, accurate, specific, and reproducible for the determination of rofecoxib and celecoxib, and appropriate for pharmacokinetic studies to quantitate these therapeutic agents in patients with arthritis conditions.
High performance liquid chromatography of mebudipine: application to pharmacokinetic study.
  • S. Bohlooli, F. Keyhanfar, M. Mahmoudian
  • Chemistry, Biology
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2001
TLDR
A suitable, convenient and simple HPLC assay for pharmacokinetic study of mebudipine in rabbits was developed, with no interfering peaks from endogenous components in blank plasma chromatograms.
RP‐HPLC Assay of Rofecoxib from Pharmaceutical Dosage Forms and Human Plasma and Its Drug Dissolution Studies
ABSTRACT A high performance liquid chromatographic (HPLC) method is described for the determination of rofecoxib (RFC) in bulk drug, tablets, and human plasma samples. The methods are linear over the
Application of a new high performance liquid chromatography method to the pharmacokinetics of dibudipine in rats.
  • S. Bohlooli, F. Keyhanfar, S. Ghiaee, M. Mahmoudian
  • Chemistry, Biology
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2003
TLDR
The HPLC method was simple and convenient and could be applied to investigations of the pharmacokinetics of dibudipine in the rat, and with the exception of the brain, the concentrations of the drug in all tissues were higher than the plasma levels.
Comparison of derivative spectrophotometric and liquid chromatographic methods for the determination of rofecoxib.
TLDR
Two different UV spectrophotometric methods were developed for the determination of rofecoxib in bulk form and in pharmaceutical formulations and they successfully applied for the assay of pharmaceutical dosage form.
Pharmacokinetics of Rofecoxib
TLDR
COX-2 inhibitors represent a major therapeutic advance in terms of gastrointestinal safety; however, long-term safety in other organ systems and with concomitant drug administration still remain to be proven.
Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects
TLDR
An updated overview on the physicochemical, pharmaceutical, pharmacokinetic and pharmacodynamic vistas of rofecoxib is provided.
Selective inhibition of prostacyclin synthase activity by rofecoxib
TLDR
An inhibitory effect of rofecoxib is demonstrated on PGIS activity in human umbilical vein endothelial cells and in PGIS‐enriched bovine aortic microsomal fractions, which is not observed by using other anti‐inflammatory compounds.
Bioequivalence Study and Pharmacokinetic Evaluation of Two Brands of Rofecoxib 25 mg Tablets in a Lebanese Population
TLDR
This was an open-label, randomized, double blind, single dose, two-way, non-replicated cross over design, with 19 days wash-out, and the extraction procedure and HPLC analysis were adapted from previously published methods.
...
...

References

SHOWING 1-8 OF 8 REFERENCES
The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs.
  • R. Halpin, L. Geer, K. Vyas
  • Medicine, Biology
    Drug metabolism and disposition: the biological fate of chemicals
  • 2000
TLDR
Radioactivity distributed rapidly to tissues, with the highest concentrations of the i.v. dose observed in most tissues by 5 min and by 30 min in liver, skin, fat, prostate, and bladder.
Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.
Scientific rationale for specific inhibition of COX-2.
TLDR
Evidence suggests that the GI toxicity associated with NSAID use is primarily the result of inhibition ofCOX-1, and antiinflammatory effects are largely due to inhibition of COX-2, and compounds that may be 100 to 300-fold more effective inhibitors of COx-2 and that therefore may have lower risks for toxicity as well as more potent anti inflammatory effects have been developed, but are not yet available for clinical use.
Scientific rationale for specific inhibition of COX-2.
  • W. Bolten
  • Biology, Medicine
    The Journal of rheumatology. Supplement
  • 1998
TLDR
Evidence suggests that the GI toxicity associated with NSAID use is primarily the result of inhibition ofCOX-1, and antiinflammatory effects are largely due to inhibition of COX-2, and compounds that may be 100 to 300-fold more effective inhibitors of COx-2 and that therefore may have lower risks for toxicity as well as more potent anti inflammatory effects have been developed, but are not yet available for clinical use.
Diagnosis and treatment of nonsteroidal anti-inflammatory drug
  • J Pharm Pharmaceut Sci (www.ualberta.ca/~csps)
  • 2000
pharmacody - namics of sotalol enantiomers are influenced by inflammation with no pharmacokinetics conse
  • Pharm Res
  • 1997
pharmacodynamics of sotalol enantiomers are influenced by inflammation with no pharmacokinetics consequence
  • Pharm Res
  • 1997